Immunomedics recently transitioned from a research and development organization into a fully-integrated global biopharmaceutical company.
This evolution has been years in the making — made possible through the concerted and persistent efforts of our colleagues and medical and business partners around the globe. Our model exudes the benefits of a nimble and flexible biotech that is focused on creating breakthrough science and therapies, while leveraging our connected infrastructure and global partner ecosystem to drive scale and operational excellence across the business.
Over the past three years, Immunomedics has made substantial progress towards its commitments to patients, medical practitioners and shareholders. Our global footprint has expanded to include offices and facilities in the United States and Germany with over 400 employees, and a precedent-setting partnership with Everest Medicines in Greater China and select ASEAN countries.
The Spring of 2020 marked a major milestone for Immunomedics with the first FDA approval for our antibody-drug conjugate (ADC) for the treatment of people with metastatic triple-negative breast cancer and also the first FDA-approved anti-Trop-2 ADC.
From here, we will continue our mission of delivering new, life-changing treatments to people living with cancer around the world.